Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q2 2023 · 10-Q
Revenue$9.98B$9.98B−11.4% vs Q2 2022 Net Income$1.38B$1.38B−31.9% vs Q2 2022 EPS Diluted$0.78$0.78−31.6% vs Q2 2022 Operating Income$1,542,000,000−35.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$696,000,000−65.7% Margins · derivedOperating margin15.5%−5.7 pt vs Q2 2022
Net margin13.8%−4.1 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 3, 2023 · 34 d after period end